Replies to post #259034 on Innovation Pharmaceuticals Inc (IPIX)

[Empiricst1]

I agree, but though the IBD/Crohn's/ulcerative colitis market is huge, it remains so far away without prying a few bucks out of an OM or an ABSSSI treatment sale/licensing. This lack of movement even affects the potential of Kevetrin (which may or may not be huge, as we all know). But would be nice to find out. The constant putting all off into the future is strange. And as time ticks off, potential competitors in every area progress.

[frrol]

Approaching April 2019 and no cash left and having lost a term sheet, a licensing deal looks less and less likely. This is not because of "manipulators" or any other conspiracy. The remaining pipeline (B and K) just isn't as proven and as attractive as it might need to be to attract strong interest. Management has been very optimistic, and has expressed that optimism. But true interest in our pipeline from objective sources, while difficult, is a much better gauge. The dropped term sheet, languishing share price, and difficulty raising affordable capital from even pharma-experienced investors or bio-cap funds are our only independent indications. They don't bode well.

Rooting for Leo!